# Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Source: https://onco.cc/trials/nct05737706/  
OnCo record `nct05737706` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MRTX1133 in Non-small-cell lung cancer and Rectal cancer, run by Mirati Therapeutics Inc., recorded as terminated on the registry.

## Summary

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation is a phase 1 interventional study registered as NCT05737706 by Mirati Therapeutics Inc., with 63 participants recorded, started 2023-03-06 and due to reach its primary completion in 2025-03-10. Interventions recorded: MRTX1133. Conditions recorded: Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma.

Linked to the drug MRTX1133 because the registry names it among its interventions and Non-small-cell lung cancer and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Also known as: MRTX1133 phase 1/2
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05737706
- Phase: 1
- Setting: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
- Sponsor: Mirati Therapeutics Inc.
- Enrolled: 63

## Notes

- Registry status on 24 September 2026: terminated, 63 participants (actual), started 6 March 2023 and completed 10 March 2025, United States sites only; no results posted and no publication found in Europe PMC. It was the first KRAS G12D inhibitor in the clinic; the G12D programmes now in phase 3 are zoldonrasib's RASolute 305 and 309.

## Sources

- ClinicalTrials.gov NCT05737706: https://clinicaltrials.gov/study/NCT05737706

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [MRTX1133](https://onco.cc/drugs/mrtx1133/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- terms: [KRAS mutation subtypes (G12C, G12D, G12V)](https://onco.cc/terms/kras-mutation-subtypes/), [Pancreatic cancer: the failed and stopped programmes and why](https://onco.cc/terms/pancreatic-failed-programmes/)

---
JSON: https://onco.cc/api/v1/entities/nct05737706.json